Tenders

Medicine Discount Contracts in Accordance with Section 130A Paragraph 8 Sgb V as Part of Open House Procedures

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Ixekizumab, Atc L04ac13 (Obo) for the Period July 1St, 2024 - June 30Th, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Dornase Alfa, Atc R05cb13 (Obo) for the Period July 1St, 2024 - June 30Th, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Piribedil, Atc N04bc08 (Obo) for the Period July 1, 2024 - June 30, 2025 (One-Year Extension Option)

Medicine Discount Contracts in Accordance with Section 130A Paragraph 8 Sgb V as Part of Open House Procedures

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Propranolol (Exclusively Lse), Atc C07aa05 (Obo) for the Period July 1St, 2024 - June 30Th, 2026

Open House Discount Contracts 2024-07

Openhouse Procedure Various Active Pharmaceutical Ingredients from October 1St, 2024

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion Within the Framework of the So-Called Open House Procedure.

Open House Biologics Discount Agreements 2024-03 - Omalizumab